2 exciting ASX healthcare shares to buy for the long term

Here’s why PolyNovo Ltd (ASX:PNV) and this ASX healthcare share could be great long term options for investors right now…
The post 2 exciting ASX healthcare shares to buy for the long term appeared first on Motley Fool Australia. –

Doctor pressing digitised screen with array of icons including one entitled health insurance

I continue to believe that the healthcare sector is a great place to invest with a long term view.

This is due to favourable industry tailwinds which look set to support demand for healthcare services for a long time to come.

While I think CSL Limited (ASX: CSL) would be a strong buy right now for this reason, it isn’t the only healthcare share to consider.

Here are two exciting ASX healthcare shares to look at:

Opthea Ltd (ASX: OPT)

Opthea is a developer of novel biologic therapies for the treatment of eye diseases. The key attraction to the company for me is the OPT-302 combination therapy which delivered very strong study results last year. If its upcoming Phase 3 trial proves just as successful, then the future could be very bright for the company.

The current standard of care treatments for wet age-related macular degeneration had sales of over US$3.7 billion in 2018. This gives it a sizeable market opportunity. In addition to this, the company is targeting diabetic macular edema (DME), which had sales of over US$6.2 billion in 2018. Though, it is worth noting that I’m not as confident that its DME trials will be as successful following some mixed phase 2a results. Another positive is that Opthea has a very strong balance sheet and appears well-funded to see OPT-302 through its trials.

PolyNovo Ltd (ASX: PNV)

Another ASX healthcare share to look at is PolyNovo. It is a growing medical device company which is marketing the increasingly popular NovoSorb technology. NovoSorb is a family of proprietary medical grade polymers that can be utilised for the manufacture of novel medical devices. These biocompatible polymers are designed to support different functions of the body and then biodegrade into by-products that can be easily absorbed and excreted.

Its NovoSorb Biodegradable Temporising Matrix (BTM) product is the one that I’m most excited about. It is a wound dressing which is designed to treat full-thickness wounds and burns. Management estimates that it currently has a sizeable $1.5 billion addressable market. However, it is looking to expand its use into other markets and sees an opportunity to take the product into the hernia and breast treatment markets. These would add a further $6 billion to its addressable market if successful.

These stocks could rocket in a Post-COVID world (FREE STOCK REPORT)

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.

Find out the names of our 3 Post COVID Stocks – For FREE!

*Returns as of 6/8/2020

More reading

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. and POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post 2 exciting ASX healthcare shares to buy for the long term appeared first on Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!